CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
61.34
+0.51 (0.84%)
At close: May 27, 2025, 4:00 PM
61.36
+0.02 (0.03%)
After-hours: May 27, 2025, 7:57 PM EDT
CVS Health Stock Forecast
Stock Price Forecast
According to 14 professional analysts, the 12-month price target for CVS Health stock ranges from a low of $62 to a high of $84. The average analyst price target of $75.14 forecasts a 22.50% increase in the stock price over the next year.
Price Target: $75.14 (+22.50%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CVS Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 6 | 5 | 5 | 5 | 3 |
Buy | 7 | 7 | 8 | 8 | 8 | 8 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 17 | 16 | 16 | 16 | 16 | 14 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Truist Securities | Truist Securities | Strong Buy Maintains $82 → $84 | Strong Buy | Maintains | $82 → $84 | +36.94% | May 12, 2025 |
Wells Fargo | Wells Fargo | Buy Maintains $76 → $84 | Buy | Maintains | $76 → $84 | +36.94% | May 6, 2025 |
RBC Capital | RBC Capital | Buy Maintains $74 → $81 | Buy | Maintains | $74 → $81 | +32.05% | May 5, 2025 |
UBS | UBS | Hold Maintains $67 → $71 | Hold | Maintains | $67 → $71 | +15.75% | May 2, 2025 |
Barclays | Barclays | Buy Maintains $73 → $82 | Buy | Maintains | $73 → $82 | +33.68% | May 2, 2025 |
Financial Forecast
Revenue This Year
390.71B
from 370.66B
Increased by 5.41%
Revenue Next Year
406.88B
from 390.71B
Increased by 4.14%
EPS This Year
6.17
from 3.66
Increased by 68.58%
EPS Next Year
7.08
from 6.17
Increased by 14.77%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 422.6B | 444.7B | 481.5B | ||
Avg | 390.7B | 406.9B | 431.5B | ||
Low | 374.0B | 380.8B | 385.9B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 14.0% | 13.8% | 18.3% | ||
Avg | 5.4% | 4.1% | 6.1% | ||
Low | 0.9% | -2.5% | -5.2% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 6.83 | 8.15 | 9.45 | ||
Avg | 6.17 | 7.08 | 8.06 | ||
Low | 5.65 | 5.98 | 6.36 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 86.5% | 32.1% | 33.5% | ||
Avg | 68.6% | 14.8% | 13.8% | ||
Low | 54.5% | -3.1% | -10.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.